Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Igor Odintsov, MD

Title(s)Assistant Professor, Pathology
SchoolSchool of Medicine
Address1825 4th Street, #M2371
San Francisco CA 94158
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping Mutations. J Thorac Oncol. 2025 Sep 20. Pecci F, Agrawal P, Ross JS, Ricciuti B, Nakazawa S, Di Federico A, Aldea M, Garbo E, Santo V, Gariazzo E, Makarem M, Haradon D, Odintsov I, Baine M, Travis W, Yang SR, Ugalde Figueroa PA, Gray KD, Nishino M, Mayoral Penalva M, Jänne PA, Sholl LM, Awad MM, Chaft JE. PMID: 40983286.
      View in: PubMed   Mentions:
    2. High-Grade Early-Onset Prostate Cancer: Assessment of TMPRSS2::ERG -Negative Tumors Suggests Low Frequency of Germline Alterations and a Pathogenic Role for HOXB13. Am J Surg Pathol. 2025 Dec 01; 49(12):1279-1287. Maharjan D, Siegmund S, Michalova K, Odintsov I, Hornick JL, Nair V, Idrees MT, Collins K, Gordetsky JB, Osunkoya AO, Cheng L, Miyamoto H, Sangoi AR, Wu DJ, Ricci C, Mollica V, Raspollini MR, Contreras F, Bernal MPP, Fernandez IM, Rodriguez A, Lobo A, Mohanty SK, Sharma S, Goksel M, Acosta AM. PMID: 40745946.
      View in: PubMed   Mentions:
    3. MUC4-positive Fibroblastoma: A Distinctive Hyalinized Spindle Cell Neoplasm With Aberrant Nuclear Beta-catenin Expression and Frequent Biallelic Inactivation of APC. Am J Surg Pathol. 2025 Nov 01; 49(11):1125-1132. Repetto F, Odintsov I, Sholl LM, Hornick JL, Anderson WJ. PMID: 40548388.
      View in: PubMed   Mentions:
    4. Efficacy and Safety of Tarlatamab in a Patient With Advanced Delta-Like Ligand 3-Positive Large Cell Neuroendocrine Lung Carcinoma and Untreated Brain Metastases: A Case Report. JCO Precis Oncol. 2025 Jun; 9:e2500184. Gariazzo E, Laaksonen S, Canty S, De Almeida GR, Odintsov I, Santo V, Garbo E, Pecci F, Aldea M, Oser MG, Sholl L, Sands JM, Ricciuti B. PMID: 40499092.
      View in: PubMed   Mentions:
    5. Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements. Cancer Discov. 2025 Jun 03; 15(6):1129-1140. Nakazawa S, Pecci F, Odintsov I, Gazgalis D, Gottlieb FH, Ricciuti B, Zullo L, Alessi JV, Di Federico A, Aldea M, Garbo E, Gandhi MM, Saini A, Feng WW, Jiang J, Baldacci S, Facchinetti F, Makarem M, Locquet MA, Haratani K, Haradon D, Besse B, Italiano A, Remon J, Lavaud P, Vasseur D, Planchard D, Sato Y, Watanabe Y, Owen S, Cortot AB, Mahran H, Forster MD, Niu J, Tomasini P, Leong SS, Tay K, Esteban E, Minchom A, Kizilbash SH, Cruz-Correa M, Yu KP, Zhang X, Chen P, Sangem M, Che J, Sholl LM, Jänne PA, Awad MM. PMID: 40202082.
      View in: PubMed   Mentions:
    6. Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy. Cancer Discov. 2025 Jun 03; 15(6):1141-1158. Febres-Aldana CA, Vojnic M, Odintsov I, Zhang T, Cheng R, Beach CZ, Lu D, Mattar MS, Gazzo AM, Gili L, Harshan M, Ameri A, Machnicki S, Xiao X, Lockwood WW, Zhou XY, Yao Q, Drilon A, Rekhtman N, Shah N, Li A, Liu Z, Yang SR, Davare MA, Ladanyi M, Somwar R. PMID: 39965191; PMCID: PMC12133426.
      View in: PubMed   Mentions:
    7. Genetic correlates of malignancy in TFE3-rearranged PEComa: a series of 14 cases. Histopathology. 2025 Sep; 87(3):436-445. Papke DJ, Odintsov I, Mahadevan NR, Fletcher CD, Hanna J. PMID: 40462401; PMCID: PMC12360456.
      View in: PubMed   Mentions:
    8. Genomic Profiling of Cardiac Angiosarcoma Reveals Novel Targetable KDR Variants, Recurrent MED12 Mutations, and a High Burden of Germline POT1 Alterations. Clin Cancer Res. 2025 Mar 17; 31(6):1091-1102. Odintsov I, Papke DJ, George S, Padera RF, Hornick JL, Siegmund SE. PMID: 39820259.
      View in: PubMed   Mentions:
    9. Malignant Giant Cell Tumor of Bone: A Clinicopathologic Series of 28 Cases Highlighting Genetic Differences Compared With Conventional, Atypical, and Metastasizing Conventional Tumors. Am J Surg Pathol. 2025 Jun 01; 49(6):539-553. Papke DJ, Kovacs SK, Odintsov I, Hornick JL, Raskin KA, Newman ET, Lozano-Calderón S, Chebib I, Hung YP, Nielsen GP. PMID: 40077813.
      View in: PubMed   Mentions:
    10. Odontogenic Myxoma Harbors Widespread Loss of Heterozygosity and Not Trisomies. Am J Surg Pathol. 2025 May 01; 49(5):523-525. Odintsov I, Kleijn TG, Ryall ST, Ameline B, Dong F, Szuhai K, Baumhoer D, Dal Cin P, Cleven AHG, Papke DJ. PMID: 40071647.
      View in: PubMed   Mentions:
    11. BRAF Gene Fusions in Melanoma: First Kinase Domain Duplication, New Fusion Partners, and Clinical Outcomes. Am J Surg Pathol. 2025 May 01; 49(5):429-438. Odintsov I, Davis D, Pissaloux D, Tirode F, de la Fouchardiere A, Hanna J. PMID: 39943800.
      View in: PubMed   Mentions:
    12. Clear Cell Stromal Tumor of the Lung: Clinicopathologic, Immunohistochemical, and Molecular Characterization of Eight Cases. Mod Pathol. 2025 Jan; 38(1):100632. Odintsov I, Isaacson A, Fritchie KJ, Hung YP, Khoshnoodi P, Sholl LM, Fletcher CDM, Anderson WJ. PMID: 39424226.
      View in: PubMed   Mentions:
    13. HER2 Antibody-Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor. Clin Cancer Res. 2024 Oct 15; 30(20):4701-4713. Zhang T, Febres-Aldana CA, Liu Z, Dix JM, Cheng R, Dematteo RG, Lui AJW, Khodos I, Gili L, Mattar MS, Lisanti J, Kwong C, Linkov I, Tipping MJ, de Stanchina E, Odintsov I, Ladanyi M, Somwar R. PMID: 39120576; PMCID: PMC11479846.
      View in: PubMed   Mentions:
    14. Epithelioid Fibrous Histiocytoma Is on a Continuum With Superficial ALK -rearranged Myxoid Spindle Cell Neoplasm : A Clinicopathologic Series of 35 Cases Including Alternate RET and NTRK3 Fusions. Am J Surg Pathol. 2024 Dec 01; 48(12):1568-1579. DeSimone MS, Odintsov I, Tsai HK, Dickson BC, Alomari AK, Hornick JL, Fletcher CDM, Papke DJ. PMID: 39329254.
      View in: PubMed   Mentions:
    15. Preclinical evaluation of targeted therapies for central nervous system metastases. Dis Model Mech. 2024 Sep 01; 17(9). Pfeil AJ, Hale JD, Zhang TS, Wakayama K, Miyazaki I, Odintsov I, Somwar R. PMID: 39344915; PMCID: PMC11463968.
      View in: PubMed   Mentions:
    16. Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and MDM2 Amplification. JCO Precis Oncol. 2024 Sep; 8:e2400241. Elkrief A, Odintsov I, Smith RS, Vojnic M, Hayashi T, Khodos I, Markov V, Liu Z, Lui AJW, Bloom JL, Offin MD, Rudin CM, de Stanchina E, Riely GJ, Somwar R, Ladanyi M. PMID: 39259915; PMCID: PMC11404768.
      View in: PubMed   Mentions:
    17. Myxoid Inflammatory Myofibroblastic Sarcoma: Clinicopathologic Analysis of 25 Cases of a Distinctive Sarcoma With Deceptively Bland Morphology and Aggressive Clinical Behavior. Am J Surg Pathol. 2024 Aug 01; 48(8):1005-1016. Papke DJ, Odintsov I, Dickson BC, Nucci MR, Agaimy A, Fletcher CDM. PMID: 38717131.
      View in: PubMed   Mentions:
    18. A visual-language foundation model for computational pathology. Nat Med. 2024 03; 30(3):863-874. Lu MY, Chen B, Williamson DFK, Chen RJ, Liang I, Ding T, Jaume G, Odintsov I, Le LP, Gerber G, Parwani AV, Zhang A, Mahmood F. PMID: 38504017; PMCID: PMC11384335.
      View in: PubMed   Mentions:
    19. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC. J Thorac Oncol. 2024 May; 19(5):732-748. Odintsov I, Makarem M, Nishino M, Bachert SE, Zhang T, LoPiccolo J, Paweletz CP, Gokhale PC, Ivanova E, Saldanha A, Rudin CM, Lockwood WW, Ladanyi M, Somwar R, Jänne PA, Sholl LM. PMID: 38154514; PMCID: PMC11957432.
      View in: PubMed   Mentions:
    20. Prognostic and predictive biomarkers in non-small cell lung carcinoma. Pathology. 2024 Mar; 56(2):192-204. Odintsov I, Sholl LM. PMID: 38199926.
      View in: PubMed   Mentions:
    21. Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. Nat Cancer. 2023 Oct; 4(10):1526. Miyazaki I, Odintsov I, Ishida K, Lui AJW, Kato M, Suzuki T, Zhang T, Wakayama K, Kurth RI, Cheng R, Fujita H, Delasos L, Vojnic M, Khodos I, Yamada Y, Ishizawa K, Mattar MS, Funabashi K, Chang Q, Ohkubo S, Yano W, Terada R, Giuliano C, Lu YC, Bonifacio A, Kunte S, Davare MA, Cheng EH, de Stanchina E, Lovati E, Iwasawa Y, Ladanyi M, Somwar R. PMID: 37814012; PMCID: PMC10597837.
      View in: PubMed   Mentions:
    22. Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. Nat Cancer. 2023 09; 4(9):1345-1361. Miyazaki I, Odintsov I, Ishida K, Lui AJW, Kato M, Suzuki T, Zhang T, Wakayama K, Kurth RI, Cheng R, Fujita H, Delasos L, Vojnic M, Khodos I, Yamada Y, Ishizawa K, Mattar MS, Funabashi K, Chang Q, Ohkubo S, Yano W, Terada R, Giuliano C, Lu YC, Bonifacio A, Kunte S, Davare MA, Cheng EH, de Stanchina E, Lovati E, Iwasawa Y, Ladanyi M, Somwar R. PMID: 37743366; PMCID: PMC10518257.
      View in: PubMed   Mentions:
    23. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies. J Thorac Oncol. 2024 01; 19(1):106-118. Udagawa H, Nilsson MB, Robichaux JP, He J, Poteete A, Jiang H, Heeke S, Elamin YY, Shibata Y, Matsumoto S, Yoh K, Okazaki S, Masuko T, Odintsov I, Somwar R, Ladanyi M, Goto K, Heymach JV. PMID: 37678511; PMCID: PMC11161205.
      View in: PubMed   Mentions:
    24. Infantile Sinonasal Myxoma Is Clinically and Genetically Distinct From Other Myxomas of the Craniofacial Bones and From Desmoid Fibromatosis. Am J Surg Pathol. 2023 11 01; 47(11):1301-1315. Odintsov I, Dong F, Guenette JP, Fritchie KJ, Jo VY, Fletcher CDM, Papke DJ. PMID: 37678343.
      View in: PubMed   Mentions:
    25. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification. J Thorac Oncol. 2023 09; 18(9):1165-1183. Elkrief A, Odintsov I, Markov V, Caeser R, Sobczuk P, Tischfield SE, Bhanot U, Vanderbilt CM, Cheng EH, Drilon A, Riely GJ, Lockwood WW, de Stanchina E, Tirunagaru VG, Doebele RC, Quintanal-Villalonga Á, Rudin CM, Somwar R, Ladanyi M. PMID: 37182602; PMCID: PMC10524759.
      View in: PubMed   Mentions:
    26. Integrating Molecular Sequencing Into the Pathological Diagnosis of Clinically Suspected Non-Small Cell Lung Carcinomas. Mod Pathol. 2023 05; 36(5):100126. Lo YC, Bauer AH, Odintsov I, Siegmund SE, Sholl LM, Dong F. PMID: 36842187.
      View in: PubMed   Mentions:
    27. Primary Clear Cell Sarcoma of Bone: Clinicopathologic Study of a Rare Presentation. Am J Surg Pathol. 2023 03 01; 47(3):354-360. Odintsov I, Jagannathan JP, Al-Ibraheemi A, Selig MK, Newman ET, Fletcher CDM, Nielsen GP, Hornick JL. PMID: 36730915.
      View in: PubMed   Mentions:
    28. MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer. Mol Cancer Res. 2022 05 04; 20(5):722-734. Iyer SR, Odintsov I, Schoenfeld AJ, Siau E, Mattar MS, de Stanchina E, Khodos I, Drilon A, Riely GJ, Ladanyi M, Somwar R, Davare MA. PMID: 35149545; PMCID: PMC9081178.
      View in: PubMed   Mentions:
    29. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discov. 2022 05 02; 12(5):1233-1247. Schram AM, Odintsov I, Espinosa-Cotton M, Khodos I, Sisso WJ, Mattar MS, Lui AJW, Vojnic M, Shameem SH, Chauhan T, Torrisi J, Ford J, O'Connor MN, Geuijen CAW, Schackmann RCJ, Lammerts van Bueren JJ, Wasserman E, de Stanchina E, O'Reilly EM, Ladanyi M, Drilon A, Somwar R. PMID: 35135829; PMCID: PMC9394398.
      View in: PubMed   Mentions:
    30. Corrigendum: Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation. Cold Spring Harb Mol Case Stud. 2022 Apr; 8(3). Choo F, Odintsov I, Nusser K, Nicholson K, Davis L, Corless CL, Stork L, Somwar R, Ladanyi M, Davis JL, Davare MA. PMID: 35483883; PMCID: PMC9059788.
      View in: PubMed   Mentions:
    31. CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma. Cancer Res. 2022 03 15; 82(6):1110-1127. Odintsov I, Ortiz MV, Khodos I, Mattar MS, Lui AJW, Kohsaka S, de Stanchina E, Bender JLG, Ladanyi M, Somwar R. PMID: 35074756; PMCID: PMC8930606.
      View in: PubMed   Mentions:
    32. Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation. Cold Spring Harb Mol Case Stud. 2022 01; 8(1). Choo F, Odintsov I, Nusser K, Nicholson KS, Davis L, Corless CL, Stork L, Somwar R, Ladanyi M, Davis JL, Davare MA. PMID: 35012940; PMCID: PMC8744497.
      View in: PubMed   Mentions:
    33. Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling. Dis Model Mech. 2022 01 01; 15(1). Smith RS, Odintsov I, Liu Z, Lui AJ, Hayashi T, Vojnic M, Suehara Y, Delasos L, Mattar MS, Hmeljak J, Ramirez HA, Shaw M, Bui G, Hartono AB, Gladstone E, Kunte S, Magnan H, Khodos I, De Stanchina E, La Quaglia MP, Yao J, Laé M, Lee SB, Spraggon L, Pratilas CA, Ladanyi M, Somwar R. PMID: 34841430; PMCID: PMC8807576.
      View in: PubMed   Mentions:
    34. Determination of biological behavior of solitary fibrous tumors: correlation of expression of Ki-67, TPX2 and TERT mRNA subunit level and NAB2-STAT6 fusion compared to morphological aspects of SFTs. Neoplasma. 2022 Jan; 69(1):28-35. Krsková L, Odintsov I, Fabián O, Hroudová P, Mrhalová M. PMID: 34818026.
      View in: PubMed   Mentions:
    35. Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers. J Thorac Oncol. 2021 07; 16(7):1149-1165. Odintsov I, Mattar MS, Lui AJW, Offin M, Kurzatkowski C, Delasos L, Khodos I, Asher M, Daly RM, Rekhtman N, de Stanchina E, Ganji G, Ladanyi M, Somwar R. PMID: 33839363; PMCID: PMC9261529.
      View in: PubMed   Mentions:
    36. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions. Clin Cancer Res. 2021 06 01; 27(11):3154-3166. Odintsov I, Lui AJW, Sisso WJ, Gladstone E, Liu Z, Delasos L, Kurth RI, Sisso EM, Vojnic M, Khodos I, Mattar MS, de Stanchina E, Leland SM, Ladanyi M, Somwar R. PMID: 33824166; PMCID: PMC8172458.
      View in: PubMed   Mentions:
    37. ROS1 at the Crossroads of Clinical Oncology, Molecular Diagnostics, and Drug Development. JCO Oncol Pract. 2021 01; 17(1):15-16. Odintsov I, Somwar R, Ladanyi M, Drilon A. PMID: 33434449.
      View in: PubMed   Mentions:
    38. NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors. Commun Biol. 2020 12 16; 3(1):776. Somwar R, Hofmann NE, Smith B, Odintsov I, Vojnic M, Linkov I, Tam A, Khodos I, Mattar MS, de Stanchina E, Flynn D, Ladanyi M, Drilon A, Shinde U, Davare MA. PMID: 33328556; PMCID: PMC7745027.
      View in: PubMed   Mentions:
    39. RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation. Dis Model Mech. 2020 Dec 14. Hayashi T, Odintsov I, Smith RS, Ishizawa K, Liu AJW, Delasos L, Kurzatkowski C, Tai H, Gladstone E, Vojnic M, Kohsaka S, Suzawa K, Liu Z, Kunte S, Mattar MS, Khodos I, Davare MA, Drilon A, Cheng E, Stanchina E, Ladanyi M, Somwar R. PMID: 33318047; PMCID: PMC7888717.
      View in: PubMed   Mentions:
    40. Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor. Clin Cancer Res. 2021 02 15; 27(4):1184-1194. Ogura K, Somwar R, Hmeljak J, Magnan H, Benayed R, Momeni Boroujeni A, Bowman AS, Mattar MS, Khodos I, de Stanchina E, Jungbluth A, Asher M, Odintsov I, Hartono AB, LaQuaglia MP, Slotkin E, Pratilas CA, Lee SB, Spraggon L, Ladanyi M. PMID: 33229458; PMCID: PMC8212565.
      View in: PubMed   Mentions:
    41. Expression of molecules of the Wnt pathway and of E-cadherin in the etiopathogenesis of human thymomas. Oncol Lett. 2020 Mar; 19(3):2413-2421. Vodicka P, Krskova L, Odintsov I, Krizova L, Sedlackova E, Schutzner J, Zamecnik J. PMID: 32194741; PMCID: PMC7039126.
      View in: PubMed   Mentions:
    42. Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer. JCO Precis Oncol. 2019; 3. Suzawa K, Offin M, Schoenfeld AJ, Plodkowski AJ, Odintsov I, Lu D, Lockwood WW, Arcila ME, Rudin CM, Drilon A, Yu HA, Riely GJ, Somwar R, Ladanyi M. PMID: 31157314; PMCID: PMC6541452.
      View in: PubMed   Mentions: 32     Fields:    
    43. A blast from the past: ROS1 on the brain. Oncotarget. 2019 Mar 01; 10(18):1664-1666. Odintsov I, Somwar R, Davare MA. PMID: 30899438; PMCID: PMC6422201.
      View in: PubMed   Mentions:
    Igor's Networks
    Concepts (152)
    Derived automatically from this person's publications.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-16-gff1bd585 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.